Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: September 12, 2005
Last updated: November 5, 2007
Last verified: November 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2006
  Estimated Primary Completion Date: No date given